ReviewBMC nephrology2025
Exostosin 1/exostosin 2-associated membranous nephropathy in undifferentiated connective tissue disease: a case report and literature review.
Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal involvement in undifferentiated connective tissue disease (UCTD) is rare and not well characterized, with membranous nephropathy (MN) representing an uncommon but clinically significant manifestation. While exostosin 1/exostosin 2 (EXT 1/EXT 2)-associated MN has been increasingly recognized in systemic autoimmune diseases such as lupus and Sjögren’s syndrome, its association with UCTD has not been previously reported. CASE PRESENTATION: We present the case of a 32-year-old male with UCTD who developed nephrotic syndrome and was found to have exostosin 1/exostosin 2 (EXT 1/EXT 2)-associated membranous nephropathy (MN) on renal biopsy. The patient exhibited serological markers including ANA, anti-SSA/Ro, and anti-ribosomal P protein antibodies, alongside characteristic pathological features of secondary MN with IgG1-dominant deposits and negative PLA2R/THSD7A staining. He was successfully treated with prednisone, tacrolimus, and hydroxychloroquine, achieving significant reduction in proteinuria within two months.
conclusionsThis case underscores the diagnostic utility of EXT 1/EXT 2 immunohistochemistry in identifying autoimmune-mediated MN in UCTD and supports the use of combined immunosuppressive therapy. To our knowledge, this is the first reported case of EXT 1/EXT 2-associated MN in a patient with UCTD, thereby expanding the spectrum of renal pathology in this condition and underscoring the importance of precise histological classification to guide targeted treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.